SG11201909941QA - Stable formulations of anti-tigit antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof - Google Patents
Stable formulations of anti-tigit antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereofInfo
- Publication number
- SG11201909941QA SG11201909941QA SG11201909941QA SG11201909941QA SG 11201909941Q A SG11201909941Q A SG 11201909941QA SG 11201909941Q A SG11201909941Q A SG 11201909941QA SG 11201909941Q A SG11201909941Q A SG 11201909941QA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- rule
- antibodies
- new jersey
- tigit
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 5
- 238000009472 formulation Methods 0.000 title abstract 4
- 101100519207 Mus musculus Pdcd1 gene Proteins 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 102220240796 rs553605556 Human genes 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000037581 Persistent Infection Diseases 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/547—Chelates, e.g. Gd-DOTA or Zinc-amino acid chelates; Chelate-forming compounds, e.g. DOTA or ethylenediamine being covalently linked or complexed to the pharmacologically- or therapeutically-active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
International Publication Number WO 2018/204405 Al (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) PCT (19) World Intellectual Property Organization International Bureau (43) International Publication Date 08 November 2018 (08.11.2018) W I P I (51) International Patent Classification: A61K 39/00 (2006.01) A61P 31/12 (2006.01) A61K 39/395 (2006.01) A61P 35/00 (2006.01) (21) International Application Number: PCT/US2018/030516 (22) International Filing Date: 01 May 2018 (01.05.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/500,278 02 May 2017 (02.05.2017) US (71) Applicant: MERCK SHARP & DOHME CORP. [US/US]; 126 East Lincoln Avenue, Rahway, New Jersey 07065-0907 (US). (72) Inventors; and (71) Applicants US only): DE, Arnab [IN/US]; 2000 Gal- loping Hill Road, Kenilworth, New Jersey 07033 (US). NARASIMHAN, Chakravarthy Nachu [US/US]; 2000 Galloping Hill Road, Kenilworth, New Jersey 07033 (US). (74) Common Representative: MERCK SHARP & DOHME CORP.; 126 East Lincoln Avenue, Rahway, New Jersey 07065-0907 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, (54) Title: STABLE FORMULATIONS OF ANTI-TIGIT ANTIBODIES ALONE AND IN COMBINATION WITH PRO- GRAMMED DEATH RECEPTOR 1 (PD-1) ANTIBODIES AND METHODS OF USE THEREOF pH Stability of anti—TIGIT antibody formulation 6.4 6.2 6.0 = 5.8 • • A— 5C —A— 25C 40C Upper Limit 5.6 5.4 5.2 5.0 0 00 O C 3 6 9 12 Time on stability (Months) FIG.1 (57) : The present invention relates to stable formulations of antibodies against T cell immunoreceptor with Ig and ITIM do- mains (TIGIT), optionally further containing an anti-human programmed death receptor 1 (PD-1) antibody or antigen binding fragment thereof. Also provided are methods of treating various cancers and chronic infections with the formulations of the invention. [Continued on next page] WO 2018/204405 Al 1#110figinigE1010010101HOHOIREBER TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(11)) as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) with sequence listing part of description (Rule 5.2(a))
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762500278P | 2017-05-02 | 2017-05-02 | |
PCT/US2018/030516 WO2018204405A1 (en) | 2017-05-02 | 2018-05-01 | Stable formulations of anti-tigit antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201909941QA true SG11201909941QA (en) | 2019-11-28 |
Family
ID=64016405
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201909941Q SG11201909941QA (en) | 2017-05-02 | 2018-05-01 | Stable formulations of anti-tigit antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof |
SG10202111905PA SG10202111905PA (en) | 2017-05-02 | 2018-05-01 | Stable formulations of anti-tigit antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10202111905PA SG10202111905PA (en) | 2017-05-02 | 2018-05-01 | Stable formulations of anti-tigit antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof |
Country Status (16)
Country | Link |
---|---|
US (1) | US20200354453A1 (en) |
EP (1) | EP3618855A4 (en) |
JP (2) | JP7402693B2 (en) |
KR (1) | KR20190142394A (en) |
CN (1) | CN110603052A (en) |
AU (1) | AU2018261080A1 (en) |
BR (1) | BR112019022698A2 (en) |
CA (1) | CA3061050A1 (en) |
CL (1) | CL2019003145A1 (en) |
CO (1) | CO2019012356A2 (en) |
IL (1) | IL270175B2 (en) |
MA (1) | MA50661A (en) |
MX (1) | MX2019013033A (en) |
RU (1) | RU2019138519A (en) |
SG (2) | SG11201909941QA (en) |
WO (1) | WO2018204405A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114106182A (en) * | 2022-01-26 | 2022-03-01 | 中山康方生物医药有限公司 | Antibodies against TIGIT and uses thereof |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101562580B1 (en) | 2007-06-18 | 2015-10-22 | 머크 샤프 앤 도메 비.브이. | Antibodies to human programmed death receptor PD-1 |
CN115925931A (en) * | 2015-08-14 | 2023-04-07 | 默沙东公司 | anti-TIGIT antibody |
CA3062061A1 (en) | 2017-05-01 | 2018-11-08 | Agenus Inc. | Anti-tigit antibodies and methods of use thereof |
RU2019138507A (en) | 2017-05-02 | 2021-06-02 | Мерк Шарп И Доум Корп. | ANTIBODY AGAINST LAG3 AND JOINT ANTIBODY AGAINST LAG3 AND ANTIBODY AGAINST PD-1 |
WO2019171253A1 (en) * | 2018-03-07 | 2019-09-12 | Pfizer Inc. | Anti-pd-1 antibody compositions |
EP3876978A4 (en) * | 2018-11-07 | 2022-09-28 | Merck Sharp & Dohme Corp. | Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof |
JP2022512294A (en) * | 2018-12-14 | 2022-02-03 | モルフォシス・アーゲー | Antibody preparation |
EP3985025A4 (en) * | 2019-06-13 | 2023-09-13 | Green Cross Corporation | Antibody to tigit and use thereof |
EP3999537A1 (en) * | 2019-07-19 | 2022-05-25 | Ichnos Sciences SA | Lyophilized antibody formulation |
CN112741804A (en) * | 2019-10-31 | 2021-05-04 | 上海君实生物医药科技股份有限公司 | Stable formulations containing anti-PD-L1 antibodies |
US20230080706A1 (en) * | 2020-01-21 | 2023-03-16 | Innovent Biologics (Suzhou) Co., Ltd. | Recombinant fully human anti-tigit monoclonal antibody formulation, method for preparing same and use thereof |
CN115243718A (en) * | 2020-01-24 | 2022-10-25 | 瑞泽恩制药公司 | Stable antibody formulations |
CN114507284B (en) * | 2020-05-09 | 2023-05-26 | 华博生物医药技术(上海)有限公司 | Antibodies against TIGIT, methods of preparation and uses thereof |
TW202200616A (en) | 2020-06-18 | 2022-01-01 | 美商建南德克公司 | Treatment with anti-tigit antibodies and pd-1 axis binding antagonists |
CN111718415B (en) * | 2020-07-03 | 2021-02-23 | 上海洛启生物医药技术有限公司 | anti-TIGIT nano antibody and application thereof |
TW202216778A (en) | 2020-07-15 | 2022-05-01 | 美商安進公司 | Tigit and cd112r blockade |
AR125753A1 (en) | 2021-05-04 | 2023-08-09 | Agenus Inc | ANTI-TIGIT ANTIBODIES, ANTI-CD96 ANTIBODIES AND METHODS OF USE OF THESE |
CN116059341A (en) * | 2021-07-23 | 2023-05-05 | 中山康方生物医药有限公司 | Pharmaceutical composition and use thereof |
WO2023010094A2 (en) | 2021-07-28 | 2023-02-02 | Genentech, Inc. | Methods and compositions for treating cancer |
WO2023056403A1 (en) | 2021-09-30 | 2023-04-06 | Genentech, Inc. | Methods for treatment of hematologic cancers using anti-tigit antibodies, anti-cd38 antibodies, and pd-1 axis binding antagonists |
WO2023198116A1 (en) * | 2022-04-14 | 2023-10-19 | Beigene Switzerland Gmbh | Stable high concentration arginine formulations containing pd-1 antibody and methods of use thereof |
WO2023240058A2 (en) | 2022-06-07 | 2023-12-14 | Genentech, Inc. | Prognostic and therapeutic methods for cancer |
WO2024030458A2 (en) * | 2022-08-04 | 2024-02-08 | Merck Sharp & Dohme Llc | Methods for determining one or more critical quality attributes of co-formulated antibodies |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2827180T3 (en) * | 2006-10-06 | 2021-05-20 | Amgen Inc | Stable Antibody Formulations |
WO2011008770A2 (en) * | 2009-07-14 | 2011-01-20 | Biogen Idec Ma Inc. | Methods for inhibiting yellow color and peroxide formation in a composition |
EP2399604A1 (en) * | 2010-06-25 | 2011-12-28 | F. Hoffmann-La Roche AG | Novel antibody formulation |
WO2012135408A1 (en) * | 2011-03-31 | 2012-10-04 | Merck Sharp & Dohme Corp. | Stable formulations of antibodies to human programmed death receptor pd-1 and related treatments |
US20140227250A1 (en) * | 2012-08-23 | 2014-08-14 | Merck Sharp & Dohme Corp. | Stable formulations of antibodies to tslp |
US9873740B2 (en) * | 2013-07-16 | 2018-01-23 | Genentech, Inc. | Methods of treating cancer using PD-1 axis binding antagonists and TIGIT inhibitors |
EA036311B1 (en) * | 2014-08-19 | 2020-10-26 | Мерк Шарп И Доум Корп. | Anti-tigit antibodies |
BR112017013385A2 (en) * | 2014-12-23 | 2018-02-06 | Bristol-Myers Squibb Company | antibodies to tigit |
EP3349792A1 (en) * | 2015-09-14 | 2018-07-25 | Compass Therapeutics LLC | Compositions and methods for treating cancer via antagonism of the cd155/tigit pathway and tgf- |
US20190010224A1 (en) * | 2015-12-22 | 2019-01-10 | Merck Sharp & Dohme Corp. | Formulations of engineered anti-il-10 antibodies |
-
2018
- 2018-05-01 CN CN201880029167.7A patent/CN110603052A/en active Pending
- 2018-05-01 MA MA050661A patent/MA50661A/en unknown
- 2018-05-01 WO PCT/US2018/030516 patent/WO2018204405A1/en unknown
- 2018-05-01 JP JP2019559836A patent/JP7402693B2/en active Active
- 2018-05-01 RU RU2019138519A patent/RU2019138519A/en unknown
- 2018-05-01 SG SG11201909941Q patent/SG11201909941QA/en unknown
- 2018-05-01 AU AU2018261080A patent/AU2018261080A1/en active Pending
- 2018-05-01 MX MX2019013033A patent/MX2019013033A/en unknown
- 2018-05-01 SG SG10202111905PA patent/SG10202111905PA/en unknown
- 2018-05-01 BR BR112019022698A patent/BR112019022698A2/en unknown
- 2018-05-01 IL IL270175A patent/IL270175B2/en unknown
- 2018-05-01 CA CA3061050A patent/CA3061050A1/en active Pending
- 2018-05-01 EP EP18793797.4A patent/EP3618855A4/en active Pending
- 2018-05-01 US US16/610,188 patent/US20200354453A1/en active Pending
- 2018-05-01 KR KR1020197035375A patent/KR20190142394A/en not_active Application Discontinuation
-
2019
- 2019-10-30 CL CL2019003145A patent/CL2019003145A1/en unknown
- 2019-11-01 CO CONC2019/0012356A patent/CO2019012356A2/en unknown
-
2023
- 2023-11-06 JP JP2023189493A patent/JP2024016177A/en active Pending
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114106182A (en) * | 2022-01-26 | 2022-03-01 | 中山康方生物医药有限公司 | Antibodies against TIGIT and uses thereof |
Also Published As
Publication number | Publication date |
---|---|
JP2024016177A (en) | 2024-02-06 |
MX2019013033A (en) | 2020-02-05 |
BR112019022698A2 (en) | 2020-05-19 |
SG10202111905PA (en) | 2021-12-30 |
IL270175B1 (en) | 2023-05-01 |
WO2018204405A1 (en) | 2018-11-08 |
AU2018261080A1 (en) | 2019-11-07 |
US20200354453A1 (en) | 2020-11-12 |
CO2019012356A2 (en) | 2020-01-17 |
JP7402693B2 (en) | 2023-12-21 |
KR20190142394A (en) | 2019-12-26 |
EP3618855A1 (en) | 2020-03-11 |
IL270175B2 (en) | 2023-09-01 |
MA50661A (en) | 2020-08-05 |
CA3061050A1 (en) | 2018-11-08 |
EP3618855A4 (en) | 2021-02-17 |
IL270175A (en) | 2019-12-31 |
CL2019003145A1 (en) | 2020-07-10 |
CN110603052A (en) | 2019-12-20 |
RU2019138519A3 (en) | 2021-08-30 |
RU2019138519A (en) | 2021-06-02 |
JP2020518600A (en) | 2020-06-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201909941QA (en) | Stable formulations of anti-tigit antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof | |
SG11201910134SA (en) | Stable formulations of anti-ctla4 antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof | |
SG11201804765UA (en) | Combination of anti-pd-1 antibodies and bispecific anti-cd20/anti-cd3 antibodies to treat cancer | |
SG11201808979UA (en) | Novel b7-h3 binding molecules, antibody drug conjugates thereof and methods of use thereof | |
SG11201900480YA (en) | Anti-tim-3 antibodies | |
SG11201803956UA (en) | Anti-dr5 antibodies and methods of use thereof | |
SG11201909955XA (en) | Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies | |
SG11201810933QA (en) | Anti-c5 antibodies and uses thereof | |
SG11201907753TA (en) | Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof | |
SG11201806624XA (en) | Deposition of molybdenum thin films using a molybdenum carbonyl precursor | |
SG11201807437XA (en) | Antibodies specific to human poliovirus receptor (pvr) | |
SG11201903857UA (en) | Antibodies to pd-1 and uses thereof | |
SG11201900138TA (en) | Programmed death 1 ligand 1 (pd-l1) binding proteins and methods of use thereof | |
SG11201910182RA (en) | Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof | |
SG11201908719QA (en) | Biomarkers and car t cell therapies with enhanced efficacy | |
SG11201808242UA (en) | Methods for inhibiting angiogenesis in a subject in need thereof | |
SG11201907580SA (en) | Combination therapies for treatment of bcma-related cancers and autoimmune disorders | |
SG11201810883TA (en) | Combination therapy | |
SG11201811003PA (en) | Anti-pd-l1 antibodies and uses thereof | |
SG11201810023QA (en) | Anti-tim-3 antibodies and methods of use thereof | |
SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
SG11201903830TA (en) | Blockade of cd7 expression and chimeric antigen receptors for immunotherapy of t-cell malignancies | |
SG11201805048SA (en) | Bispecific anti-cd20/anti-cd3 antibodies to treat acute lymphoblastic leukemia | |
SG11201804178YA (en) | Pd1 and/or lag3 binders | |
SG11201807176XA (en) | TGFß1-BINDING IMMUNOGLOBULINS AND USE THEREOF |